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Background: Foamy viruses (FVs) have developed a unique budding strategy within the retrovirus family. FV
release requires co-expression and a highly specific interaction between capsid (Gag) and glycoprotein (Env), which
cannot be complemented by heterologous Env proteins. The interaction domain in FV Env has been mapped in
greater detail and resides mainly in the N-terminal tip of the cytoplasmic domain of the Env leader peptide subunit.
In contrast, the corresponding domain within Gag is less well defined. Previous investigations suggest that it is
located within the N-terminal part of the protein.
Results: Here we characterized additional Gag interaction determinants of the prototype FV (PFV) isolate using a
combination of particle release, GST pull-down and single cycle infectivity analysis assays. Our results demonstrate
that a minimal PFV Gag protein comprising the N-terminal 129 aa was released into the supernatant, whereas
proteins lacking this domain failed to do so. Fine mapping of domains within the N-terminus of PFV Gag revealed
that the N-terminal 10 aa of PFV Gag were dispensable for viral replication. In contrast, larger deletions or
structurally deleterious point mutations in C-terminally adjacent sequences predicted to harbor a helical region
abolished particle egress and Gag – Env protein interaction. Pull-down assays, using proteins of mammalian and
prokaryotic origin, support the previous hypothesis of a direct interaction of both PFV proteins without requirement
for cellular cofactors and suggest a potential direct contact of Env through this N-terminal Gag domain.
Furthermore, analysis of point mutants within this domain in context of PFV vector particles indicates additional
particle release-independent functions for this structure in viral replication by directly affecting virion infectivity.
Conclusions: Thus, our results demonstrate not only a critical function of an N-terminal PFV Gag motif for the
essential capsid - glycoprotein interaction required for virus budding but also point out additional functions that
affect virion infectivity.
Keywords: Foamy virus, Budding, Protein-protein Interaction, Helical motifBackground
Glycoproteins of lipid membrane enveloped viruses harbor
the main essential determinants of viral particle tropism.
This includes host cell receptor and/or co-receptor recog-
nition as well as the machinery required for fusion of viral
and cellular membranes during virion entry. As a conse-
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reproduction in any medium, provided the ordependent on successful incorporation of their particular
glycoprotein(s) during the budding step of particle morpho-
genesis in the infected host cell to ensure subsequent pro-
ductive infection of target cells. For orthoretroviruses
different, but related mechanisms of glycoprotein encapsi-
dation into budding virions are apparent. This explains the
orthoretroviral capacity for specific incorporation of the
cognate glycoprotein but also pseudotyping with glycopro-
teins from unrelated viral families (reviewed in [1]). Factors,
such as co-trafficking or recruitment of capsid and glyco-
proteins to specific membrane domains, direct or indirect
interaction between both proteins, as well as steric. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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specific virus capsids, influence glycoprotein inclusion.
Spuma- or foamy virus (FVs) budding is reported to
occur at different cellular membranes/locations [2-4].
All known FV species with the exception of equine FV
(EFV) are thought to bud predominantly into intracellu-
lar compartments, a phenotype that correlates with an
ER retrieval signal located at the C-terminus of the re-
spective glycoproteins [5-7]. FVs are unique among ret-
roviruses, as budding requires co-expression of both the
capsid (Gag) and the viral glycoprotein (Env) (reviewed
in [8,9]). A very specific interaction of both proteins,
presumably taking place at the trans-Golgi network, is
necessary for this step in replication since the FV Gag
protein lacks a membrane-targeting signal [3,10-12]. The
glycoprotein domain targeted by the capsid was mapped
to the N-terminus of cytoplasmic domain (CyD) of the FV
Env signal- or leader peptide (LP) subunit (gp18LP for
prototype FV, PFV) [13,14]. Two evolutionary conserved
tryptophan residues (W10, W13 in PFV Env) of the Env LP
CyD are known to be essentially involved in the Gag inter-
action. This special function of a retroviral glycoprotein
signal peptide in virion morphogenesis is the result of the
unusual biosynthesis of FV Env proteins that lack
cotranslational removal of the signal peptide required for
targeting to the secretory pathway [13]. Instead, FV Env
proteins are processed post-translationally, late during cell
surface transport, giving rise to a glycoprotein complex in
released FV particles composed of a LP subunit with type
II membrane orientation, an extracellular surface (SU)
subunit (gp80SU for PFV), and a type I membrane top-
ology transmembrane (TM) subunit (gp48™ for PFV)
[13-16].
Unlike orthoretroviruses the FV Gag protein does not
show the classical tripartite processing pattern into
matrix (MA), capsid (CA) and nucleocapsid subunits
(Figure 1A) (reviewed in [17]). Although the FV Gag
protein apparently lacks a membrane targeting signal,
several other sequence and structural motifs within FV
Gag proteins have been characterized that have import-
ant roles for the biological function of the FV capsid
protein (reviewed in [9]). These include four putative
coiled-coil (CC1-4) motifs found in PFV Gag, of which
only CC2 and CC3 are evolutionary conserved in many
but not all FV species (Figure 1A and ref. [18]). CC2 is is
required for PFV Gag-Gag interactions and is essential
for capsid assembly whereas CC3 appears to mediate at-
tachment of PFV capsids to the light chains of dynein
motor proteins exploited by FVs for transport to the
centrosome in target cells [19]. No function has been
assigned to CC4. The first putative motif (CC1) is pre-
dicted with a low CC-forming score for FVs of great
apes, but is absent in FV Gag proteins of most old word
and new world monkeys as well as in the feline, bovineor equine FV Gag proteins. The putative PFV CC1 motif
resides in the N-terminal part of Gag that is suggested
by previous studies to harbor the poorly defined inter-
action domain with the CyD of the Env LP subunit
[14,20-22]. For example it was demonstrated that the
N-terminal 297 aa of PFV Gag, containing the essential
late assembly (L) domain, are sufficient for an efficient
Gag release into the supernatant when co-expressed with
PFV Env [20,23]. Furthermore, small deletions within the
N-terminal part of the protein abolished capsid egress and
N-terminal fusion of protein tags to PFV Gag appears to
interfere with viral egress in tag size dependent manner
[20,22,24]. Finally, surface plasmon resonance studies
using recombinant N-terminal protein fragments of feline
FV (FFV) Gag (corresponding to PFV Gag aa1-180) and
FFV Env peptides or recombinant protein fragments (cor-
responding to PFV Env aa1-28 or aa1-61) suggest a direct
low affinity interaction between both proteins [14,21].
Furthermore, these studies confirm the importance of the
conserved tryptophan residues with the Env LP subunit
for this process. However, they failed to provide evidence
for a role of the cytoplasmic targeting retention
signal (CTRS) motif, responsible for capsid assembly at
the centrosome, in the interaction with the viral glycopro-
tein [14,21,25].
Here we report a thorough investigation of the PFV
Gag – Env interaction by using a pull-down assay in
combination with particle release studies and single
cycle replication assays using recombinant PFV vector
particles. The analysis demonstrates a specific direct
Gag-Env interaction that requires a minimal domain com-
prising amino acid 11–129 of PFV Gag. Interestingly,
functional data of selected mutants of N-terminal amino
acids of this minimal domain indicate that this PFV capsid
structure might have additional Env-interaction-independ-
ent functions in the FV replication cycle.
In the course of this manuscript preparation and re-
view, the X-ray structure of an N-terminal fragment of
PFV Gag in complex with peptides of the PFV Env LP
subunit was published [26]. In line with the results of
our study this PFV Gag-Env structure demonstrates an
interaction of the N-terminus of PFV Env LP subunit
with PFV Gag through a hydrophobic pocket involving
an N-terminal amphipathic α-helix.
Results
Deletion of the N-terminal 130 aa of PFV Gag abolishes
particle release
Previous studies have suggested, that the PFV Gag-Env
interaction is mediated by amino-acids in the N-terminal
region of the Gag [14,20-22]. To identify a suitable Gag
construct for establishment of a eukaryotic pull-down
assay to study the Gag-Env interaction and to re-examine
the requirements for PFV Env-dependent particle egress,
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of Gag truncations (Figure 1B). All PFV Gag proteins
contained a C-terminal eGFP-HA tag to allow detection
of the differently sized proteins in Western blot analysis
with the same efficiency using tag-specific antibodies.
C-terminal tagging was chosen since it was previously
shown that C- but not N-terminal PFV Gag fusion pro-
teins have wild type-like particle release features [24]. In
line with this transient transfection of 293T cells with dif-
ferent PFV Gag packaging constructs, in combination with
a full-length PFV Env packaging construct, revealed an ef-
ficient PFV Env-dependent particle egress for full-length
PFV Gag proteins with either C-terminal HA- or EGFP-
HA-tag (Figure 2A, lane 15, 18). Successive C-terminal de-
letion of PFV Gag (up to aa 295) did not significantlyFigure 1 Schematic illustration of the mammalian Gag and Env expre
protein. Structural and functional domains are indicated in differentially sha
marked by a solid arrow and potential secondary cleavage sites by dashed
(B) Schematic outline of the PFV Gag expression constructs. All constructs
-tag (HH) or EGFP-HA-6xHis-tag (EGFP-HH) indicated as white boxes. (C) Sc
outline of the wild type full-length PFV Env coding sequences are show as
boxes as explained below. The major processing sites in gp130Env are mark
Below an outline of the individual Env expression constructs is shown. All c
W denotes the conserved tryptophan residues at position 10 and 13 of the
retention signal; L: PSAP late-assembly (L)-domain motif; A: YXXLGL assemb
of the leader peptide (LP); FP: fusion peptide of the transmembrane subun
surface subunit; Y: N-glycosylation sites.reduce particle release as long as the PSAP L-domain was
retained (Figure 2A, lane 19–23). A truncated Gag pro-
tein comprising only the N-terminal 129 aa still sup-
ported capsid export, but at significantly reduced
levels compared to all other tested C-terminal trunca-
tions containing the PSAP L-domain (Figure 2A, lane
24). In contrast, no particles were released upon dele-
tion of aa 1–129 of either the full-length Gag protein
or a protein comprising the first 295 aa from cells co-
expressing Env (Figure 2A, lane 16, 17), although both
contained the L-domain motif and were expressed at
similar levels as Gag proteins still supporting particle
egress (Figure 2A, lane 1–12).
This suggests the first 129 aa of PFV Gag to be suffi-
cient for Env-dependent particle egress and to harborssion constructs. (A) Schematic outline of the PFV Gag precursor
ded boxes as explained below. The major processing site in p71Gag is
arrows. Numbers indicate amino acid positions in PFV Gag.
harbor a C-terminal flexible (Gly4Ser1)3 linker (L) and either a HA-6xHis
hematic outline of the PFV Env expression constructs. On top the
grey boxes with different hydrophobic sequence indicated as black
ed by solid arrows. Numbers indicate amino acid positions in PFV Env.
onstructs harbor a C-terminal flexible (Gly4Ser1)3 linker (L) and GST-tag.
PFV Env ORF. CC: coiled-coil motif; CTRS: cytoplasmic targeting and
ly domain motif; GR: glycine-arginine rich box; h: hydrophobic domain
it (TM); MSD: membrane-spanning domain of the TM subunit; SU:
Figure 2 (See legend on next page.)
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Figure 2 Release and interaction characteristics of various PFV Gag – Env protein combinations. (A) Representative Western blot analysis
of 293T cell lysates (cells) and subtilisin-digested viral particles preparations (particles) purified by ultracentrifugation through 20% sucrose,
transiently transfected with different combinations of Gag and Env expression constructs as indicated. Gag proteins were detected using a
polyclonal anti-HA serum. Cells were transfected with pczHFVenvEM002 and lane 2, 14: pcziCLEGHH (EGHH); lane 3, 15: pcziPG4 CLHH (wt CLHH);
lane 4, 16: pcziPG4 130–648 CLEGHH (130–648 CLEGHH); lane 5, 17: pcziPG4 130–295 CLEGHH (130–295 CLEGHH); lane 6, 18: pcziPG4 CLEGHH
(wt CLEGHH); lane 7, 19: pcziPG4 1–621 CLEGHH (1–621 CLEGHH); lane 8, 20: pcziPG4 1–450 CLEGHH (1–450 CLEGHH); lane 9, 21: pcziPG4 1–350
CLEGHH (1–350 CLEGHH);; lane 10, 22: pcziPG4 1–310 CLEGHH (1–310 CLEGHH); lane 11, 23: pcziPG4 1–295 CLEGHH (1–295 CLEGHH); lane 12, 24:
pcziPG4 1–129 CLEGHH (1–129 CLEGHH); or lane 1, 13: only pUC19 (mock). (B-C) Representative Western blot analysis of pull-down assays using
mixed lysates of 293T cells transiently transfected with different GST-tagged Env or EGFP-HH-tagged Gag expression constructs as indicated.
Samples of Gag expressing cell lysates corresponding to 10% of the input (input) for the pull-down assay are shown to the left, samples of
proteins eluted by boiling in SDS-PAGE loading buffer from pelleted glutathione-sepharose beads (pull-down) are shown to the right. Prey (Gag
and ctrls) proteins were detected using a polyclonal anti-HA serum (α-HA), bait (Env and ctrls) proteins using a polyclonal anti-GST serum (α-GST).
Shown are pull-down assays combining 293T cell lysates transiently transfected with various prey or bait expression constructs as indicated. Preys:
EGHH: pcziCLEGHH; wt CLHH: pcziPG4 CLHH; wt CLEGHH: pcziPG4 CLEGHH; 1–621 CLEGHH: pcziPG4 1–621 CLEGHH; 1–450 CLEGHH: pcziPG4
1–450 CLEGHH; 1–350 CLEGHH: pcziPG4 1–350 CLEGHH; 1–310 CLEGHH: pcziPG4 1–310 CLEGHH; 1–295 CLEGHH: pcziPG4 1–295 CLEGHH; 1–180
CLEGHH: pcziPG4 1–180 CLEGHH; 1–155 CLEGHH: pcziPG4 1–155 CLEGHH; 1–129 CLEGHH: pcziPG4 1–129 CLEGHH. Baits: mock: pCAGGS; GST:
pCAG GST; wt: pCAG Env1-60 CLGST; W/A: pCAG Env1-60 CLGST W/A.
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tein although a loss of Env requirement in particle release
cannot be formally excluded from our experiments. How-
ever, in previous studies similar C-terminal Gag trunca-
tions were demonstrated to retain their Env-dependence
in particle egress [20].
Examining the specificity of the PFV Gag – Env
interaction by a eukaryotic pull-down assay
In order to map the domains of PFV-Gag that interact
with the Env-LP in further detail a GST-based pull–down
assay employing a mammalian cell expression system was
developed. In this assay different PFV Gag prey proteins
were incubated with an Env-GST fusion protein bait, com-
prising residues 1–60 of Env (Env-LP-GST wt) (Figure 1C).
Alternatively, a derivative (Env-LP-GST W/A) where the
essential W10 and W13 of Env were substituted with ala-
nine, just GST (GST), or mock transfected cell lysates
were used as bait to examine the specificity of any interac-
tions detected (Figure 1C).
It has been demonstrated previously that full length
PFV Gag harbouring the GR-boxes is unsuitable for a
pull-down due to problems associated with high back-
ground and poor specificity of co-immunoprecipitation
[18]. Therefore PFV Gag fusion protein preys with differ-
ent C-terminal deletions were first tested for suitability in
this assay (Figure 2B). These data show that the Gag pro-
teins extending beyond the amino-terminal 450 residues
display weak but significant non-specific binding with
the affinity matrix (Figure 2B, compare lanes 9–11, 13–15
and 17–19 with 12, 16 and 20). Neither nuclease pre-
treatment of cell lysates nor variation of salt conditions
improved the specificity of the pull down of these larger
Gag baits (data not shown).
However, a Gag fragments comprising the amino-
terminal 450 residues displayed strong specific binding
with the wild type bait and little nonspecific bindingwith the controls (Figure 2B, compare lane 21–23 with 24).
Therefore, various Gag fragments up to the amino-
terminal 450 residues were then tested for their ability to
interact with the different baits (Figure 2C). Detailed ana-
lysis of Env interaction with the different Gag-fusion pro-
tein baits indicated that the first 180 aa were sufficient for
maintaining a specific Env tryptophan residue-dependent
co-precipitation of Gag (Figure 2C, lane 14–21, 26–29).
Gag-fusion proteins comprising the first 129 or 155 aa
or the domain of aa 130–295 failed to specifically interact
with Env-GST bait proteins (Figure 2C, lane 12, 13, 30–
33), although they were present in the lysates at levels simi-
lar to proteins that were co-precipitated specifically (e.g.
1–180 CLEGHH) (Figure 2C, lane 3–7, 22–25). In samples
where Gag proteins were co-precipitated in an Env-specific
manner, additional shorter Gag forms were also detectable
with the C-terminal tag specific antiserum, most promin-
ent for the Gag 1–450 prey protein (Figure 2C, lane 8–21).
The nature of these, probably N-terminally truncated,
shorter forms is unclear. They might represent degradation
products, which are co-precipitated with the full-length
protein by Gag-Gag interactions, as they are already detect-
able in the cell lysates used in the pull-down assays
(Figure 2C, lane 1–7).
Taken together these results suggest that in a pull-
down assay the first 180 aa of PFV Gag are sufficient
and domains within the first 130 aa are essential for the
specific interaction with the CyD of PFV Env LP.Only the N-terminal 10 aa of PFV Gag are dispensable for
PFV particle release
To map Gag domains essential for the PFV Env inter-
action in further detail small successive N-terminal
truncation- or selected point mutants were examined in
context of the Gag 1–450 -eGFP-HA fusion protein for
their ability to support capsid release upon co-expression
Figure 3 (See legend on next page.)
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Figure 3 Release and interaction characteristics of PFV Gag proteins with small N-terminal deletions or point mutations. (A) Schematic
outline of the PFV Gag expression constructs. On top the outline of the wild type full-length PFV Gag coding sequences are shown as grey boxes
with different structural and functional domains indicated in differentially shaded boxes as described in the legend of Figure 1. (B) Coiled-coil
domain prediction using COiLS v2 algorithm (embnet.vital-it.ch/software/coils) [34] for different PFV Gag proteins. Shown are the graphic displays
of the analysis for full-length wild type protein as well as the N-terminal domains (aa 1–200) of wild type (wt), as well as mutants L17A (L17A) and
L17S (L17S). (C-D) Representative Western blot analysis of 293T cell lysates (cells) and viral particles preparations (particles) purified by
ultracentrifugation through 20% sucrose, transiently transfected with different combinations of Gag and Env expression constructs as indicated.
Gag proteins were detected using a polyclonal anti-HA serum (α-HA), Env proteins using a polyclonal anti-PFV Env LP serum (α-LP). Cells were
transfected with pczHFVenvEM002 and lane 1: pcziPG4 6–450 CLEGHH (ΔN5); lane 2: pcziPG4 11–450 CLEGHH (ΔN10); lane 3: pcziPG4 16–450
CLEGHH (ΔN15); lane 4: pcziPG4 21–450 CLEGHH (ΔN20); lane 5: pcziPG4 31–450 CLEGHH (ΔN30); lane 6: pcziPG4 41–450 CLEGHH (ΔN40); lane 7:
pcziPG4 1–450 CLEGHH (wt); lane 9: pcziPG4 1–450 L17A CLEGHH (L17A); lane 10: pcziPG4 1–450 L17S CLEGHH (L17S); lane 11: pcziPG4 1–450
P30A CLEGHH (P30A); lane 12: pcziPG4 1–450 H32A CLEGHH (H32A); lane 13: pcziPG4 1–450 R39A CLEGHH (R39A); lane 14: pcziCLEGHH (EGHH);
or lane 15: only pUC19 (mock). (E-F) Representative Western blot analysis of pull-down assays using mixed lysates of 293T cells transiently
transfected with different GST-tagged Env or EGFP-HH-tagged Gag expression constructs as indicated. Samples of Gag expressing cell lysates
corresponding to 10% of the input (input) for the pull-down assay are shown to the right, samples of proteins eluted by boiling in SDS-PAGE
loading buffer from pelleted glutathione-sepharose beads (pull-down) are shown to the left. Prey (Gag) proteins were detected using a polyclonal
anti-HA serum (α-HA), bait (Env and ctrls) proteins using a polyclonal anti-GST serum (α-GST). Shown are pull-down assays combining 293T cell
lysates transiently transfected with various prey or bait expression constructs as indicated. Preys: wt: pcziPG4 1–450 CLEGHH; ΔN5: pcziPG4 6–450
CLEGHH; ; ΔN10: pcziPG4 11–450 CLEGHH; ; ΔN15: pcziPG4 16–450 CLEGHH; ; ΔN20: pcziPG4 21–450 CLEGHH; ; ΔN30: pcziPG4 31–450 CLEGHH; ;
ΔN40: pcziPG4 41–450 CLEGHH; wt: pcziPG4 1–450 CLEGHH; L17A: pcziPG4 1–450 L17A CLEGHH; L17S: pcziPG4 1–450 L17S CLEGHH; P30A:
pcziPG4 1–450 P30A CLEGHH; L17A: pcziPG4 1–450 H32A CLEGHH; R39A: pcziPG4 1–450 R39A CLEGHH; mock: pUC19. Baits: mock: pCAGGS; GST:
pCAG GST; wt: pCAG Env1-60 CLGST; W/A: pCAG Env1-60 CLGST W/A.
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same Gag mutations on the interaction with the CyD of
the Env LP subunit were also assessed using the pull-
down assay (Figure 3E + F). Point mutations were select-
ively introduced into conserved amino acids within the
N-terminal 40 aa that have not been functionally exam-
ined previously (Figure 3A). Furthermore, a potential con-
tribution of aa L17 within the predicted CC1 previously
reported to be important for particle egress [20] was
assessed by introducing either a conservative (L17A mu-
tant) or more deleterious (L17S mutant) (Figure 3A + B).
The analysis revealed that N-terminal deletions of up to
10 aa did not alter particle release, whereas egress was
completely abolished by deletions of 15 aa or more
(Figure 3C +D, lane 1 to 7). Most of the point mutations
examined had no or only minor negative effects on Gag
protein release, except for Gag L17S, which showed a
strong reduction (Figure 3C +D, lane 7 to 13). Notably,
Gag proteins with point mutations at L17 or deletions of 15
aa or more showed reduced steady state protein levels in
cell lysate samples (Figure 3C, lane 3 to 6, 9, 10). Further-
more, in cell lysate samples of all Gag constructs that did
not support particle release a clearly diminished Env pro-
cessing was observed (Figure 3C, lane 3–6, 10). This is in
line with previous observations demonstrating that co-
expression of wild type Gag enhances Env cell surface ex-
pression as well as Env precursor processing by furin-like
proteases in the late Golgi compartment [15,27].
In agreement with the particle release analysis data, Gag
proteins with N-terminal deletions of more than 10 aa did
not co-precipitate with the CyD of the Env LP subunit
(Figure 3E). Furthermore, the pull-down assay showed an
interaction for all Gag point mutants except L17S(Figure 3F). Thus, the N-terminal 10 aa of PFV Gag,
which includes the N-terminal third of the predicted CC1
motif (aa 4–19) appears to be dispensable for the inter-
action with the Env LP subunit and for particle release. In
contrast, larger N-terminal deletions extending further
into the putative CC1 motif sequence as well as a point
mutation within CC1 interfering with the structural integ-
rity are detrimental to these processes.
In vitro interaction analysis of recombinant PFV Gag and
Env protein fragments
The results presented above strongly indicate a specific
interaction between the N-terminal domains of PFV Gag
and Env to be essential for particle egress. Nevertheless,
it remained unclear whether proteins interacted directly
or required additional factors. Therefore, fragments of
both wild type and selected mutants of PFV Gag and
Env were recombinantly expressed in E.coli and affinity-
purified proteins used for in vitro interaction analysis
studies (Figure 4A). Notably, of the different Gag variants
tested, constructs spanning the first 310 aa of PFV Gag
with a C-terminal MBP fusion tag yielded the highest
amounts of soluble recombinant protein (data not shown).
Subsequently, interaction analysis assays were per-
formed by incubation of one interaction partner of pro-
karyotic origin with lysates of transiently transfected 293T
cells containing the respective other partner or by co-
incubation of purified recombinant proteins of both inter-
action partners (Figure 4B + C). The results demonstrate
that eukaryotic PFV Env-LP-GST fusion proteins can
interact with recombinant PFV Gag proteins expressed in
E.coli with a similar specificity as observed for respective
eukaryotic cell-derived protein (Figure 4B, lane 1–4). The
Figure 4 Gag-Env interaction analysis using different combinations of prokaryotic and eukaryotic expressed proteins. (A) Schematic
outline of the prokaryotic PFV Gag expression constructs. On top the outline of the wild type full-length PFV Gag coding sequences are shown as
grey boxes with different structural and functional domains indicated as in the legend of Figure 1. (B-C) Representative Western blot analysis of
pull-down assays using various combination of lysates of 293T cells (euk.) containing different GST-tagged Env or EGFP-HH-tagged Gag proteins
or affinity purified proteins expressed in E. coli (prok.) as indicated. Samples of Gag expressing cell lysates corresponding to 10% of the input
(input) for the pull-down assay are shown to the right, samples of proteins eluted by boiling in SDS-PAGE loading buffer from pelleted
glutathione-sepharose beads (pull-down) are shown to the left. Prey (Gag and ctrls) proteins were detected using polyclonal antibodies specific
for PFV Gag (α-Gag), bait (Env) proteins using a polyclonal anti-GST serum (α-GST). Preys: 1–310: pcziPG4 1–310 CLEGHH; 1–310 MH: pET11a Gag
1–310 MH; 1–310 MH L17A: pET11a Gag 1–310 MH L17A; 1–310 MH L17S: pET11a Gag 1–310 MH L17S; 41–310 MH: pET11a Gag 41–310 MH; MH:
pET11a MH. Baits: e-wt: pCAG Env1-60 CLGST; e-W/A: pCAG Env1-60 CLGST W/A; p-wt: pET11a Env1-60 CLGST; p-W/A: pET11a Env1-60
CLGST W/A.
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Figure 5 Single-round infection analysis phenotype of PFV Gag
proteins with small N-terminal deletions and point mutations.
293T cells were co-transfected with equal amounts of PFV transfer
vector puc2MD9, Env packaging vector pcziPFVenvEM002, Pol
packaging vector pcziPol and various Gag packaging constructs
(wt: pcziPG4; ΔN5: pcziPG4 6–648; ΔN10: pcziPG4 11–648; ΔN15:
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served tryptophan residues in Env-LP as well as by dele-
tion of the N-terminal 40 aa of Gag or mutation of leucine
at position 17 into serine (Figure 4B, lane 1–12). Further-
more, an almost identical result was obtained when using
PFV Env-LP-GST fusion proteins expressed in E.coli.
Recombinant PFV Env-LP-GST was able to co-precipitate
PFV Gag expressed in mammalian cells in a tryptophan-
residue-dependent manner (Figure 4C, lane 1, 2). In
addition, recombinant PFV Gag showed a specific co-
precipitation, that was dependent on the presence of the
first 40 aa of PFV Gag (Figure 4C, lane 3–12).
A few differences were noted. First, wild type prokary-
otic PFV Gag appeared to interact less strongly with the
Env-LP-GST bait proteins than the eukaryotic Gag protein
when using similar amount of prey protein (Figure 4B + C,
lane 1–4). This phenomenon was more pronounced for
bait proteins of eukaryotic than of prokaryotic origin. Sec-
ond, the recombinant prokaryotic Gag L17A prey seemed
to be pulled down more efficiently than the respective wild
type protein at similar amounts of input (Figure 4B +C,
lane 3–6). Third, unlike mammalian cell-derived PFV Env-
LP-GST, the equivalent recombinant prokaryotic protein
specifically co-precipitated the recombinant Gag L17A and
the Gag L17S mutant proteins (Figure 4C, lane 5–8). How-
ever, the Gag L17S mutant was co-precipitated to a much
lower extent than the L17A mutant.
In summary, a specific Gag-Env interaction requiring
conserved tryptophan residues in Env-LP can be ob-
served with purified E. coli expressed protein fragments,
indicating that the interaction between Gag and Env is
direct and does not require additional co-factors. More-
over, the interaction most probably relies on the N-
terminal sequences as it requires the first 40 aa of PFV
Gag and is abolished the Gag L17S mutation.pcziPG4 16–648; ΔN20: pcziPG4 21–648; ΔN30: pcziPG4 31–648;
ΔN40: pcziPG4 41–648; L17A: pcziPG4 L17A; L17S: pcziPG4 L17S;
P30A: pcziPG4 P30A; H32A: pcziPG4 H32A; R39A: pcziPG4 R39A) or
only with pUC19 (mock) as indicated. Western blot analysis of (A)
cell lysates (cells) and (B) pelleted viral supernatants (particles) with
polyclonal antibodies specific for PFV Gag (α-Gag), and PFV
Env-LP (α-LP). The identity of the individual proteins is indicated on
the right. C) Relative infectivity of extracellular 293T cell culture
supernatants using an eGFP marker gene transfer assay was
determined 3 days post infection. The values obtained using the
wild type Gag packaging vector pcziPG4 were arbitrarily set to 100%.
Absolute titers of these plain supernatants were 5.3 ± 3.5 × 105 EGFP
ffu/ml. Means and standard deviations of three independent
experiments are shown.Particle egress and infectivity supported by full-length
PFV Gag proteins with N-terminal deletions or point
mutations
Identical N-terminal small deletion and point mutations
of respective full-length PFV Gag packaging constructs
in context of a replication-defective PFV vector system
were examined for their effect in single-round infections
(Figure 5). In general the expression patterns and par-
ticle release characteristics of the full-length Gag mu-
tants were very similar to their respective protein
fragments spanning the first 450 aa that were employed
in the pull-down assays shown above (compare
Figures 3D and 5B). Only N-terminal deletions larger
than 10 aa, as well as the L17S point mutant, completely
abolished particle egress (Figure 5B, lane 3–6, 10). The
L17A Gag mutant consistently altered the p71
Gag to
p68Gag ratio in particle samples and the H32A Gag pointmutant in some experiments showed a reduced particle
release (Figure 5B, lane 9, 12). No significant differences
in particle associated LP- and SU-subunit levels of these
two mutant particles in comparison to wild type were
detectable (Figure 5B, lane 9–12; and data not shown).
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natant of 293T cells transfected with the different Gag
packaging constructs, mirrored the particle release charac-
teristics of the individual samples quite well (Figure 5C).
Exceptions were again the L17A Gag mutant, for which no
infectivity was detectable although wild type-like particle
egress was observed, and the H32A Gag mutant, which
displayed a 25-fold reduced infectivity although particle
release was only slightly reduced in some experiments
(Figure 5B + C).
These data show that in the full-length protein context
the first 10 aa of PFV Gag are also dispensable for par-
ticle release and productive infection of target cells. In
contrast, the sequence between amino acid 11–40 appears
to be critical for particle egress. Furthermore L17 appears
to have an additional particle release-independent func-
tion critical for particle infectivity that is impaired by
mutation to alanine.
Discussion
Although specific interactions between capsid and glyco-
proteins have been reported for other retroviruses, FVs
are unique as their specific Gag – Env interaction is a
prerequisite for budding of viral particles (reviewed in
[1,8]). The major interaction domain in the FV Env pro-
tein is well defined. It spans a region of about 20 aa at
the N-terminus of the LP subunit CyD that contains two
essential conserved tryptophan residues [13,14]. In con-
trast, regions of FV Gag that are essential and sufficient
for the interaction with Env are less well characterized.
Previous studies suggested that the major interaction de-
terminants are found in the N-terminal regions of FV
Gag [14,20-22]. Furthermore, while this manuscript was
under review the X-ray structure of an N-terminal frag-
ment of PFV Gag in complex with a peptide of the PFV
Env LP subunit was determined confirming that residues
within the Gag CC1 motif are important for PFV Gag-
Env interaction [26].
Our particle release studies suggest aa 11 to 129 of
PFV Gag is sufficient for the specific interaction with
PFV Env enabling budding of virions, although longer
constructs containing the L-domain motif were secreted
more efficiently. Furthermore, our data indicate that res-
idues 11–40 of PFV Gag and their structural integrity
are essential for the interaction with PFV Env in mam-
malian cells. In support of this notion, the recent Gag
NTD-Env LP NTD structure shows that residues V14 to
R24 comprise an amphipathic α-helix that forms a major
part of the Env-LP interaction site [26].
The main observations of our particle release studies
were also confirmed by the mammalian pull-down as-
says. However, the minimal PFV Gag proteins that
showed an efficient and specific interaction with the
CyD of PFV Env LP necessarily included the predictedCC2 (aa 130–150) and (CC3 (aa 160–180) regions in
PFV Gag. CC2 and CC3, which are conserved in Gag
proteins of many but not all FV species, have been
reported to have essential function in intermolecular
PFV Gag interactions (CC2) and association of PFV
Gag with cellular proteins (CC3) [18,19]. The direct
participation of CC2 and CC3 in the interaction with
Env appears unlikely because unlike CC1 they are not
required in the particle release assays. However, their
requirement for efficient Env co-precipitation suggests
an influence of the oligomeric state of Gag on the inter-
action with Env. N-terminal PFV Gag proteins lacking
these CC domains are unlikely to form higher oligo-
meric structures, although this was not directly
addressed in this study. In line with this notion in the
Gag-Env crystal structure, aa R140 to S179, comprising
most of CC2 and CC3, form a single continuous α-helix
and are organized in a single CC domain that makes up
the majority of the Gag dimer interface [26].
Results from our interaction studies employing E. coli
produced PFV Gag and Env protein fragments also sup-
port the observations of the Gag-Env crystal structure
and a previous report for FFV that suggested a direct
interaction of both viral proteins, without a requirement
for posttranslational modification or additional cellular
proteins [14,26]. Importantly, as in the mammalian pull-
down assay the presence of the N-terminal 40 aa of PFV
Gag was essential for the interaction with Env when
using recombinant protein fragments. The reason and
potential functional significance of an apparent differ-
ence in the interaction strength of wt Gag-derived pro-
tein fragment of prokaryotic to eukaryotic origin that
were noted are currently unclear. They might be the re-
sult of different C-terminal tags on both types of
proteins used (EGFP-His-HA-tag for eukaryotic and
MBP-His-tag for prokaryotic proteins).
A major difference in our pull-down assays performed
with recombinant bait and prey proteins of different ori-
gins was a residual binding activity of prokaryotic-derived
PFV Gag L17S to prokaryotic- but not mammalian-derived
GST-Env LP. This might indicate that multiple residues of
the N-terminal Gag interaction domain contribute to the
interaction with the Env LP subunit. Alternatively, the
Gag L17S mutant protein might fold differently in eukary-
otes than in prokaryotes. In line with these results Gold-
stone and colleagues observed only a 2-fold reduction in
binding affinity for prokaryotic-derived PFV Gag L17S to
Env peptides [26].
Finally, the major phenotypes of the different Gag mu-
tants observed in the release- and pull-down assays using
PFV Gag fragments (dispensability of the N-terminal 10
aa, importance of adjacent sequences and L17 but not
other conserved aa in the N-terminus) could be confirmed
in context of the full-length proteins using a replication-
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says. Very interesting was again the phenotype of the Gag
L17A mutation that unlike the L17S mutation should retain
the putative helical structure. In contrast to the L17S mu-
tant L17A PFV Gag displayed wild type-like release charac-
teristics, but no infectivity was detectable (>3000-fold
reduced). This strongly implies an additional important
function of the Gag NTD domain that is independent of
its potential structural role for the Gag-Env interaction.
Preliminary results indicate that this mutant fails to
undergo proper intra-particle reverse transcription (data
not shown).
Our observations are in line with previous studies that
reported characterization of determinants in Gag and
Env essential for the unique budding strategy of FVs
[13,14,20-22]. Surprisingly we determined a clear dispens-
ability of the N-terminal 10 aa of PFV Gag for FV replica-
tion in all assays including PFV vector particle infectivity. A
previous study had suggested that the immediate N-
terminus of PFV Gag might be involved in the Env inter-
action since specific mutations within the first 10 aa
strongly interfered with capsid morphology and infectivity
[22]. In light of our results the phenotypes of these mutants
described previously may be a consequence of changes in
the overall structure of the capsid rather than a direct con-
tribution of the N-terminal 10 aa to the interaction with
Env. Consistent with our finding of the dispensability of the
N-terminal 10 aa of PFV Gag for viral replication is the ob-
servation that in the recently solved Gag – Env fragment
structure residues preceding PFV Gag E9 are disordered in
the crystal and that they seem to be non-essential for the
interaction with the PFV Env LP peptides [26].
Conclusion
In summary, we have characterized the essential deter-
minants in PFV Gag required for the specific interaction
with PFV Env. Whereas the Gag L-domain is needed for
efficient release, Gag aa 10–129 are sufficient for the
interaction with Env. C-terminal sequences, but not the
complete sequences of a predicted N-terminal coiled-
coil domain (CC1) in PFV Gag are essential for PFV
egress if not directly being involved in binding the CyD
of the Env LP subunit. Furthermore, our results suggest
that residues within this domain of PFV Gag have add-
itional functions for further steps in the viral replication
cycle of FVs.
Methods
Cell lines and culture conditions
The human kidney cell line 293T [28] and the human
fibrosarcoma cell line HT1080 [29] were cultivated at
37°C and 5% CO2 in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% heat-inactivated fetal
calf serum and antibiotics.Recombinant DNAs and plasmid expression constructs
The PFV 4-component vector system based on authentic
PFV genomic ORFs and consisting of the packaging
plasmids consisting of pcziPG4 (PFV Gag wt), pcziPol
(PFV Pol wt), pczHFVenvEM002 (PFV Env wt) and the
enhanced green fluorescent protein (EGFP) expressing
transfer vector puc2MD9 used for production of PFV wt
particles was described previously [24,30]. The coding
regions of the eukaryotic expressions constructs for Gag
proteins with N- or C-terminal deletions, point muta-
tions and/or C-terminal eGFP-HA tags shown schemat-
ically in Figures 1B and 3A are based on the parental
pcziPG4 packaging construct. PcziPG4 CLHH contains a
C-terminal (Gly4Ser1)3 linker (CL) and Hexa-His and
HA-tags (HH), whereas pcziPG4 CLEGHH has the eGFP
ORF inserted after the (Gly4Ser1)3 linker sequence. Fur-
thermore, several variants of the pcziPG4 CLEGHH vec-
tor with C-terminal and/or N-terminal deletions of
different length were generated. In general the PFV Gag
aa retained in the ORF are given in the name, e.g.
pcziPG4 130–295 CLEGHH expresses a PFV Gag pro-
tein encoding aa 130–295 and C-terminal CLEGHH tag.
For the point mutants the amino acid, their natural pos-
ition in the full-length protein, and the amino acid for
which is was replaced are given in the name, e.g.
pcziPG4 1–450 CLEGHH L17A encodes a Gag protein
spanning the first 450 aa of PFV Gag with C-terminal
CLEGHH tag, which has leucine 17 changed to alanine.
The coding regions of the eukaryotic expression con-
structs for the cytoplasmic domain (aa 1–60) of PFV
Env LP subunit with a C-terminal (Gly4Ser1)3 linker and
GST ORF in frame are shown schematically in Figure 1C,
and are based on the pCAGGS backbone. pCAG Env1-
60 CLGST contains aa 1–60 of the wt PFV Env ORF, its
variant pCAG Env1-60 CLGST W/A has the tryptophan
residues at position 10 and 13 changed to alanine, and
pCAG GST harbors only the (Gly4Ser1)3 linker and GST
ORF in frame. The prokaryotic expression constructs for
the wild type (pET11a Env1-60 CLGSTh) or W10,13A
mutant (pET11a Env1-60 CLGSTh W/A) cytoplasmic
domain PFV Env LP subunit, which are based on the
pET11 vector backbone (Novagen), contain the identical
coding regions as their eukaryotic counterparts except
for an additional C-terminal in frame deca-His-tag. The
prokaryotic expression constructs for PFV Gag shown
schematically in Figure 4A are based on pET11a and
contain PFV Gag coding sequences of variable length as
indicated by their name and a C-terminal in frame
maltose-binding-protein (MBP) ORF and hexa-His-tag.
For example pET11a Gag 1–310 MH L17A contains aa
1–310 of PFV Gag with leucine 17 changed to alanine.
All constructs were created by standard PCR and clon-
ing methods. Further details on the cloning procedures
and the individual plasmids are available on request.
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FV vector particles were produced as described previously
[31]. Briefly, the individual plasmids of the PFV 4-
component PFV vector system were transiently co-
transfected into 293T cells using polyethyleneimine (PEI) in
10cm dishes. 293T cells were co-transfected with different
combinations of PFV Gag and glycoprotein expression con-
structs as indicated. In experiments examining the infectiv-
ity of viral supernatants the PFV Gag and Env expression
constructs were co-transfected together with PFV Pol pack-
aging constructs (pcziPol) and a transfer vector (puc2MD9)
at the ratio of 1:1:1:1 as indicated. If necessary, empty
pUC19 plasmid was used in all experiments as stuffer to
keep the total DNA amount of transfected DNA constant
15 μg total DNA per dish. Cell-free viral vector supernatant
was harvested using 0.45 μm sterile filters (10 cm dish).
Analysis of viral infectivity
Infectivity of viral supernatants produced was deter-
mined by a flow cytometric based EGFP marker gene
transfer assay as described previously [24]. HT1080 cells
were seeded at the density of 2 × 104 cells/well in 12-
well plates 16–24 h prior to transduction. Target cells
were incubated with 1 ml of cell free viral supernatant
generated by transient transfection as described above
and 10-fold serial dilutions thereof for 4–6 h before re-
placement with normal growth medium. The percentage
of EGFP marker gene expressing cell was determined 72
h post infection (pi) by flow cytometry using a FACS
Calibur (Becton Dickinson). All transduction experi-
ments were performed at least three times and, in each
independent experiment, the titers obtained with the
untagged wild-type viruses were arbitrarily set to 100%
and those of the other samples expressed as values rela-
tive to the wt control, as described previously [32].
Western blot analysis and antisera
Cellular lysates for protein expression analysis were pre-
pared by washing the transfected 293T cells in 10 cm
dishes with PBS and following 20 min of incubation with
600 μl cell-lysis buffer (10 mM Tris/HCl pH 8.0, 140 mM
NaCl, 0.025% NaN3, 1% Triton-100) on ice. Subsequently,
cell lysates were scraped off the cell culture dishes using a
rubber policeman and centrifuged through a QIAshredder
(QIAGEN) to shear genomic DNA. After rinsing the
QIAshredder with 600 μl 2× PPPC (100 mM Tris–HCl;
pH 6.8, 24% Glycerol, 8% SDS, 0.02% Coomassie Brilliant
Blue G-250, 2% ß-Mercaptoethanol) the combined flow
through were boiled at 95°C for 10 min and used directly
for SDS-polyacrylamide gel electrophoresis or stored
at −20°C until further use.
For analysis of viral particle-associated protein compos-
ition cell-free supernatant of transfected 293T cells (10cm
dish) was harvested using a syringe and a 0.45 μm poresize sterile filter. Viral particles were concentrated by
ultracentrifugation at 25,000 rpm, 4°C in SW32 (76,755 g)
or SW40 (78,925 g) rotors through a 20% sucrose cushion.
Viral pellets were resuspended in 50 μl PBS and 50 μl 2×
PPPC was added. After boiling for 10 min at 95°C the
samples were used directly for SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) or stored at −20°C.
Cell or viral particle protein samples were separated by
SDS-PAGE using a 7.5% polyacrylamide gel and analyzed
by immunoblotting as described previously [13]. Poly-
clonal rabbit antisera specific for PFV Gag [33], for the
PFV Env LP subunit [13], or for mCherry (399C) [24] and
a polyclonal goat antisera specific for the influenza
hemagglutinine tag (BETHYL Cat No A190-107A) were
used. The gluthatione transferase (GST)-specific (4DF2)
antiserum was produced by immunization of rabbits with
recombinant proteins purified as described below. After
incubation with a suitable horseradish peroxidase (HRP)-
conjugated secondary antibody, the blots were developed
with Immobilon Western HRP substrate. The chemilu-
minescence signal was digitally recorded using a LAS-
3000 imager (Fuji).
Recombinant protein expression
Prokaryotic expression constructs were generated by
insertion of ORFs encoding C-terminally decaHis
tagged PFV Gag-MBP (maltose binding protein) [pET11a
PFVGag1-310-MH], PFV Env LP-GST [pET11a PFV-
EnvLP1-60-GSTcHis), MBP [pET11a MH] or GST [pET11-
a GSTcHis] fusion proteins into pET11 (Novagen). The
soluble fusion proteins, expressed in Escherichia coli BL21
(DE3) cultures after overnight induction with 0.5 mM
isopropylthiogalactopyranoside (IPTG) and cultivation at
14°C were affinity purified using His-Bind resin (Novagen)
according to the manufacturer’s instructions. Briefly, bacter-
ial pellets of 1 liter cultures were resuspended in 15 ml cold
lysis buffer (50 mM Tris–HCl, 150 mM NaCl [for Gag 500
mM], 1% Triton X-100, 5% Glycerol, 1% Triton X-100, 5%
Glycerol, protease inhibitor cocktail [Roche Complete].
Subsequently lysozyme, sodium-deoxycholate and DNAseI
were added to final concentrations of 2 mg/ml, 0.125%, and
10 μg/ml, respectively. Bacteria were lysed on ice by sonic-
ation (5 cycles of 30 sec each, Bandelin Sonoplus HD70,
Cycle 50%, Power 50%). Bacterial debris was pelleted by
centrifugation at 19,000 rpm (43,500xg), 4°C for 45 min
and the supernatant was sterile filtrated (0.45 μm pore size)
prior to loading onto the affinity column. For affinity purifi-
cation His-Bind-Resin columns (Novagen) with 3 ml bed
volume were used. Columns were washed with 5 volumes
ddH20, activated with 2 volumes 0.1M NiSO4 solution
followed by washing with 5 volumes washing buffer (lysis
buffer with 5 mM Imidazol). After loading of the bacterial
lysate solution and washing with 5 volumes wash buffer
bound proteins were eluted with 1 ml aliquots of lysis
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mM, 200 mM, 300 mM, 400 mM, 500 mM). Elutions
containing the largest amounts were pooled and their con-
centration determined by SDS-PAGE using a BSA standard
(0.125 to 2 mg/ml) and densitometric quantitation of the
recombinant protein bands. Recombinant proteins were
stored in 50% Glycerol at −80°C until further use.
GST pull-down assay
For the GST pull-down assay eukaryotic Gag prey and
Env bait proteins were obtained by transient transfection
of separate 293T cultures using polyethyleneimine (PEI) as
indicated above. Forty-eight hours post transfection cell
lysates were obtained by washing the transfected 293T
cells in 10 cm dishes with PBS and following 10 min of in-
cubation with 1 ml pull-down-lysis buffer (50 mM Tris/
HCl pH 7.4, 500 mM NaCl, 5 mM EDTA, 1 mM DTT, 5%
Glycerol, 1% Triton-100) at room temperature. Subse-
quently, cell lysates were scraped off the cell culture dishes
using a rubber policeman, transferred to 1.5 ml Eppendorf
tubes and incubated for another 20 min at 4°C on a
overhead-shaker. Precleared lysates were generated by
pelleting of insoluble components by centrifugation in a
precooled table top centrifuge for 6 min at 13,000 rpm
(15,500×g), 4°C. Following transfer of the supernatant to a
fresh tube the lysate was used immediately. Samples of the
lysates were mixed with 2× PPPC and used as input con-
trol for SDS-PAGE and Western blot analysis.
For each pull-down sample 15 μl of Gluthatione-
sepharose-beads (GE Healthcare, 75% slurry) were used.
Prior to incubation with the cell lysates or recombinant
proteins the combined sepharose beads were washed three
times by incubation in 1 ml cold pull-down wash buffer
(50 mM Tris/HCl pH 7.4, 150 mM NaCl, 5 mM EDTA, 1
mM DTT, 5% Glycerol, 0,1% Triton-100) for 1 min and
subsequent pelleting by centrifugatio for 1 min at 13,000
rpm (15,500×g), 4°C. After the last wash the combined
sepharose beads were resuspend in 80 μl cold pull-down
wash buffer per sample and immediately aliquoted into
fresh individual 1.5 ml tubes and stored on ice.
For pull-down assays each 450 μl of precleared 293T lys-
ate containing bait or prey proteins were combined in a
1.5 ml tube containing 80 μl of activated Gluthatione-
sepharose beads on ice. When using recombinant proteins
bait (5 μg) and prey (200 μg) proteins were combined in a
total volume of 900 μl cold pull-down-assay buffer. Fol-
lowing mixing of bait and prey samples as indicated, the
mixture was incubated for 2 h at 4°C on a overhead-
shaker. Subsequently, protein complexes bound to the
sepharose beads were pelleted by centrifugation for 20 sec
at 13,000 rpm (15,500×g), 4°C resuspended in 1 ml cold
pull-down wash buffer and incubated for 2 min at 4°C on
overhead-shaker. This washing procedure was repeated
two times before resuspending the sepharose bead pelletin 100 μl 2× PPPC. Proteins were eluted by incubating the
samples at 95°C for 10 min, followed by pelleting of the
sepharose beads for 1 min at 13,000 rpm (15,500×g), room
temperature and transfer of the supernatant to a fresh
tube. Samples were used immediately for SDS-PAGE
and Western blot analysis as described above or stored
at −20°C until further use.
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